Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767962 | 0.83 | KDM4E (0.49) | LMNAKDM4EGLAHSD17B10HTT | |
| SCHEMBL2767637 | 0.79 | HTR1A (0.54) | KMT2A | |
| SCHEMBL2770723 | 0.77 | KDM4E (0.50) | LMNAKDM4EGLAHSD17B10HTT | |
| SCHEMBL2768505 | 0.77 | KMT2A (0.71) | LMNAHSD17B10HTTKMT2A | |
| SCHEMBL1979216 | 0.77 | LMNA (0.48) | LMNAGPR183 | |
| SCHEMBL2770002 | 0.76 | L3MBTL1 (0.53) | LMNAHSD17B10KMT2APKM | |
| SCHEMBL14243575 | 0.73 | LMNA (0.43) | LMNAGPR183 | |
| SCHEMBL2766662 | 0.72 | SLC18A3 (0.48) | — | |
| SCHEMBL2768139 | 0.71 | MAPT (0.50) | HTTKMT2A | |
| SCHEMBL2766355 | 0.71 | LMNA (0.57) | LMNAKDM4EHTTKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | LMNA 3963/4885KDM4E 692/4885GLA 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.